Skip to content

About Us

Accelerating the speed that healing reaches those in need

Our Mission

Therapeutic antibodies have helped millions of people, including our own family members. Even though they are highly effective medicines, 90% of the antibodies being tested in labs today will fail to make it to clinical trials. Those that are approved by the FDA must pay for the failures - resulting in antibody therapies with costs of over $100,000.

Our mission is to leverage advances in computation to EVQLVe the cost and time of developing these life-changing therapies. We do this by failing in the computer, where it’s fast and scalable, as opposed to the lab, where it’s capital intensive, time consuming, and risky. We love to prove our skeptics wrong, and will keep doing it as we accelerate healing to those in need.

about_mission 440h
about_vision 440h

Our Vision

Therapeutic antibodies have been revolutionary in helping many people, however they can be ineffective in as many as 50% of patients. That’s because medicines are designed to work best for the greatest number of people - not to be most effective for you. With over 75% of doctor's visits leading to a one-size-fits-all prescription, the scale and urgency of this oversight requires new ways of thinking.

We envision a future where your doctor will design a medicine specifically for you - one that will work best for you, one that may only work for you. That is the dream of personalized medicine. And while reaching that future could take decades, an essential step is teaching computers to create medicines today. That is precisely what we work towards, everyday, here at EVQLV.

Andrew Satz

CEO & Co-Founder

Andrew Satz

CEO & Co-Founder

Andrew Satz is the CEO and Co-Founder of EVQLV. A data scientist by training, Andrew is a seasoned innovator with nearly two decades of experience in applied artificial intelligence. He has founded or led multiple technology companies across industries, including a biotech, where he helped bring 3 drugs from discovery to human trials. He co-developed EVQLV's antibody discovery engine, which uses a wide range of machine learning and software engineering techniques to design therapeutic antibodies. In addition to designing the foundational technology for EVQLV, Andrew has sourced and negotiated multiple licensing deals with biotech, pharmaceutical companies, and universities. He earned a B.A. in Economic-Philosophy at Columbia University and an M.S. in Data Science from Columbia University School of Engineering.

Brett Averso

CTO & Co-Founder

Brett Averso

CTO & Co-Founder

Brett Averso is the CTO and Co-Founder of EVQLV. Brett is an expert in the computational design and engineering of monoclonal antibodies and antibody fragments. As the principal architect of EVQLV’s platform, his work produced 7 de novo binding antibodies several months after the founding of EVQLV. Brett’s machine learning expertise is focused on reinforcement learning applied to generative evolutionary fitness. Brett leads the EVQLV technology team and spearheads the strategy and development of EVQLV’s platform. His technical and scientific expertise includes machine learning, antibody engineering, scalable cloud computing, immunoinformatics, and agile development. Brett started his career in data analytics as a consultant in the asset management industry. He earned a B.A. in Accounting-Finance at University Connecticut School of Business in and an M.S. in Data Science from Columbia University School of Engineering.

Simeon Simeonov

Board Member

Simeon Simeonov

Board Member

Sim is an entrepreneur, investor and startup mentor. He is the founding CTO of Swoop and IPM.ai, startups that use privacy-preserving AI to improve patient outcomes and marketing effectiveness in life sciences and healthcare. Sim was an EIR at General Catalyst Partners and technology partner at Polaris Partners where he helped start five companies the firms invested in, three of which have already been acquired.

Borys Shor

Advisor

Borys Shor

Advisor

Dr. Shor has 15 years of experience in leading oncology discovery programs and external R&D partnerships at large pharmas (Wyeth, Pfizer) and biotech companies, with specific focus on preclinical discovery and development of biologics, small molecule kinase inhibitors and nanoparticles. He is a founder and the CEO of Manhattan BioSolutions Inc. and also serves as a BioEntrepreneur-In-Residence with the New York State Biotechnology Center. Att Pfizer, Dr. Shor led cross-functional oncology research teams to develop novel antibody-drug conjugates and supported Biological License Application (BLA) filing for Inotuzumab, which was approved for the treatment of leukemia in 2017. Prior to that, Dr. Shor served as a project team leader at the department of Oncology Discovery at Wyeth Pharmaceuticals, managing the discovery and characterization of novel mTOR/PI3K kinase inhibitors for the treatment of cancer. Dr Shor earned an M.S. degree in molecular genetics from St. Petersburg State University, a Ph.D. in Molecular and Cell Biology at the SUNY Downstate Medical Center and performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D prior to joining Wyeth.

Roland Dunbrack

Advisor

Roland Dunbrack

Advisor

Roland received his PhD in Biophysics from Harvard University and now heads the Dunbrack Lab at the Fox Chase Cancer Center. Roland’s research is concentrated on statistical structural bioinformatics, the development of methods for structure prediction of proteins and protein complexes, and the application of these methods to problems in cancer biology.

Ron Lennox

Advisor

Ron Lennox

Advisor

Dr. Lennox has been an active investor and entrepreneur in early stage life science companies for over twenty five years. He has served on the boards of over eighteen companies and has been involved in the founding of seven companies, six of which were successful. He was founding CEO of Protometrix, Inc. (acquired by Life Technologies, Inc.), and also of CGI Pharmaceuticals, Inc. He holds a B.Sc. in Molecular Biology from the University of Glasgow, a PhD in Cell Biology from Oxford University and an MBA from The Wharton School of the University of Pennsylvania.

Slater Victoroff

Advisor

Slater Victoroff

Advisor

Slater Victoroff is the Founder and CTO of indico data solutions, an Enterprise AI solution for unstructured content with an emphasis on text and NLP. He has been building machine learning solutions for startups, governments, and Fortune 100 companies for the past 5 years and is a frequent speaker at AI conferences.

Victor Greiff

Advisor

Victor Greiff

Advisor

Victor Greiff is an Associate Professor at the University of Oslo (Department of Immunology) since January 2018. His group develops machine learning, computational and experimental tools for analyzing antibody and T-cell repertoires. He received his Ph.D. at Humboldt-University Berlin in 2012 and conducted his postdoctoral research in the laboratory of Sai T. Reddy (ETH Zürich, Switzerland). He is currently a member of the AIRR-C Communications Sub-committee (since 2018) and the current chair of AIRR-C Executive Sub-committee.

Vikas Goyal

Advisor

Vikas Goyal

Advisor

Vikas Goyal is a biotech entrepreneur and investor, with a particular focus on corporate strategy, capital formation, and corporate partnerships for early-stage therapeutics companies. 

Most recently, Vikas was SVP of Business Development for Pandion Therapeutics. He initially joined Pandion as a Board member and investor in 2018, then joined the company full-time in 2019 taking the company through a research collaboration with Astellas, an IPO, and the company’s acquisition by Merck for $1.85 billion in 2021. Prior to Pandion, Vikas worked as an investor at SR One, at the time the corporate venture capital arm of GlaxoSmithKline, where he started as an intern while attending Wharton. During his time at SR One, Vikas invested in and served on the boards of nearly 20 early-stage biotech companies including Morphic Therapeutics (Nasdaq: MORF), River Vision Development (acquired by Horizon), Nimbus Therapeutics, Turning Point (acquired by BMS), Spero Therapeutics (Nasdaq: SPRO) and Pandion. Earlier in his career, Vikas was a Consultant at McKinsey, a co-founder of Extera Partners, and a Business Development Manager at Infinity Pharmaceuticals. 

Supporters

Logo_Techstars
Logo_Beresford
Logo_efl
Logo_tbd
logo_creative-destruction-lab1
IMG_0854 2
Logo-SideCar-Angels
Logo - Hatter Angel Network